G. Beydagi Et Al. , "Clinical Outcomes and Contribution to Progression-Free Survival of Radionuclide Therapy with 225Ac-PSMA in Metastatic Castration-Resistant Prostate Cancer (mCDPK)," EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , vol.49, no.SUPPL 1, 2022
Beydagi, G. Et Al. 2022. Clinical Outcomes and Contribution to Progression-Free Survival of Radionuclide Therapy with 225Ac-PSMA in Metastatic Castration-Resistant Prostate Cancer (mCDPK). EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , vol.49, no.SUPPL 1 .
Beydagi, G., Selcuk, N. A., Demirci, E., Ocak, M., Toklu, T., Akcay, K., ... Caner, B.(2022). Clinical Outcomes and Contribution to Progression-Free Survival of Radionuclide Therapy with 225Ac-PSMA in Metastatic Castration-Resistant Prostate Cancer (mCDPK). EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , vol.49, no.SUPPL 1.
Beydagi, G. Et Al. "Clinical Outcomes and Contribution to Progression-Free Survival of Radionuclide Therapy with 225Ac-PSMA in Metastatic Castration-Resistant Prostate Cancer (mCDPK)," EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , vol.49, no.SUPPL 1, 2022
Beydagi, G. Et Al. "Clinical Outcomes and Contribution to Progression-Free Survival of Radionuclide Therapy with 225Ac-PSMA in Metastatic Castration-Resistant Prostate Cancer (mCDPK)." EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , vol.49, no.SUPPL 1, 2022
Beydagi, G. Et Al. (2022) . "Clinical Outcomes and Contribution to Progression-Free Survival of Radionuclide Therapy with 225Ac-PSMA in Metastatic Castration-Resistant Prostate Cancer (mCDPK)." EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , vol.49, no.SUPPL 1.
@article{article, author={G. Beydagi Et Al. }, title={Clinical Outcomes and Contribution to Progression-Free Survival of Radionuclide Therapy with 225Ac-PSMA in Metastatic Castration-Resistant Prostate Cancer (mCDPK)}, journal={EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING}, year=2022}